Estados financieros detallados de Citius Pharmaceuticals, Inc. (CTXR): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 20.0%, margen operativo -8.6%, margen neto -6.5%.
Al precio actual de $0.56, CTXR presenta beneficios negativos (P/E no significativo) y un ROE del -67.15%. La capitalización bursátil es de $6M.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $1343 | $2632 | $1753 | $893 | $152364 | $164868 | 0 | 0 | $209611 | $214250 |
| Beneficio Bruto | -$1343 | -$2632 | -$1753 | -$893 | -$152364 | -$164868 | 0 | 0 | -$209611 | -$214250 |
| I+D | $2.9M | $2.9M | $6.6M | $8.6M | $8.8M | $12.2M | $17.7M | $14.8M | $11.9M | $9.2M |
| Generales y Administrativos | $4.5M | $7.1M | $7.2M | $7.0M | $8.7M | $11.1M | $15.7M | $21.9M | $18.2M | $18.5M |
| Gastos Operativos | $7.4M | $10.0M | $13.8M | $15.6M | $17.6M | $23.4M | $33.3M | $36.7M | $42.0M | $38.3M |
| Beneficio Operativo | -$7.4M | -$10.0M | -$13.8M | -$15.6M | -$17.7M | -$23.5M | -$33.3M | -$36.7M | -$42.0M | -$38.5M |
| EBITDA | -$7.4M | -$10.0M | -$13.8M | -$15.5M | -$17.6M | -$23.4M | -$33.1M | -$36.5M | -$38.6M | -$38.2M |
| Gastos por Intereses | $8994 | $850789 | $15838 | $16443 | $15673 | $10839 | 0 | 0 | 0 | $267782 |
| Beneficio Antes de Impuestos | -$8.3M | -$10.4M | -$12.5M | -$15.6M | -$17.5M | -$23.1M | -$33.1M | -$32.0M | -$38.8M | -$38.7M |
| Impuestos | $8994 | 0 | 0 | $16443 | 0 | 0 | $576000 | $576000 | $576000 | $1.1M |
| Beneficio Neto | -$8.3M | -$10.4M | -$12.5M | -$15.6M | -$17.5M | -$23.1M | -$33.6M | -$32.5M | -$39.1M | -$37.4M |
| BPA | $-2.29 | $-1.89 | $-1.17 | $-0.77 | $-11.20 | $-5.64 | $-5.75 | $-5.57 | $-5.97 | $-3.38 |
| BPA Diluido | $-2.29 | $-1.89 | $-1.17 | $-0.77 | $-11.20 | $-5.64 | $-5.75 | $-5.57 | $-5.97 | $-3.38 |
| Acciones en Circulación (Diluidas) | $241547 | $365500 | $715458 | $1.3M | $1.6M | $4.3M | $5.8M | $6.1M | $11.6M | $11.1M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | $3.9M | $1.7M | $1.5M |
| Beneficio Bruto | -$62038 | $2.6M | -$381892 | -$718367 |
| Beneficio Operativo | -$8.4M | -$9.0M | -$32.2M | -$11.7M |
| EBITDA | -$8.3M | -$8.4M | -$30.4M | -$10.0M |
| Beneficio Neto | -$8.0M | -$8.2M | -$21.2M | -$8.9M |
| BPA | $-0.44 | $-0.38 | $-0.95 | $-0.34 |
| BPA Diluido | $-0.44 | $-0.38 | $-0.95 | $-0.34 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $294351 | $3.2M | $9.2M | $7.9M | $13.9M | $70.1M | $41.7M | $26.5M | $3.3M | $4.3M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | $818343 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $8.3M | $22.3M |
| Activos Corrientes | $892835 | $3.4M | $10.1M | $7.9M | $14.0M | $72.8M | $44.6M | $34.4M | $14.2M | $27.9M |
| Inmovilizado Material | $3742 | $3236 | $1483 | $590 | $987781 | $829851 | $650174 | $455858 | $246247 | $818694 |
| Fondo de Comercio | $1.6M | $1.6M | $1.6M | $1.6M | $9.3M | $9.3M | $9.3M | $9.3M | $9.3M | $9.3M |
| Activos Intangibles | $19.4M | $19.4M | $19.4M | $19.4M | $19.4M | $59.4M | $59.4M | $59.4M | $92.8M | $92.8M |
| Activos Totales | $22.0M | $24.4M | $31.1M | $29.0M | $43.8M | $142.4M | $114.0M | $103.6M | $116.7M | $130.9M |
| Cuentas por Pagar | $909156 | $602431 | $1.6M | $2.7M | $1.9M | $1.3M | $1.2M | $2.9M | $4.9M | $13.7M |
| Deuda a Corto | $672970 | $172970 | $172970 | $172970 | $172970 | $177237 | 0 | 0 | 0 | $1.0M |
| Pasivos Corrientes | $5.2M | $2.5M | $3.2M | $4.6M | $4.1M | $4.0M | $4.5M | $5.8M | $35.8M | $44.9M |
| Deuda a Largo | 0 | 0 | 0 | 0 | $164583 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $5.2M | $2.5M | $3.2M | $4.6M | $10.1M | $9.6M | $10.6M | $12.2M | $42.5M | $53.4M |
| Reservas | -$17.3M | -$27.7M | -$40.3M | -$55.8M | -$70.6M | -$96.0M | -$129.7M | -$162.2M | -$201.4M | -$238.8M |
| Patrimonio Neto | $16.8M | $21.9M | $27.9M | $24.4M | $33.7M | $132.2M | $102.8M | $90.8M | $70.1M | $67.6M |
| Deuda Total | $672970 | $172970 | $172970 | $172970 | $1.4M | $855471 | $678234 | $481245 | $262865 | $1.8M |
| Deuda Neta | $378619 | -$3.0M | -$9.0M | -$7.7M | -$12.5M | -$69.2M | -$41.0M | -$26.0M | -$3.0M | -$2.4M |
| Capital Circulante | -$4.3M | $955189 | $6.9M | $3.3M | $9.9M | $68.8M | $40.0M | $28.6M | -$21.6M | -$17.0M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $4.3M | $7.7M | $4.6M | $17.0M |
| Activos Totales | $130.9M | $140.4M | $132.5M | $142.3M |
| Pasivos Totales | $53.4M | $46.9M | $63.5M | $66.3M |
| Patrimonio Neto | $67.6M | $80.0M | $61.5M | $66.6M |
| Deuda Total | $1.8M | $1.8M | $808162 | $7.2M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$8.3M | -$10.4M | -$12.5M | -$15.6M | -$17.5M | -$23.1M | -$33.6M | -$32.5M | -$39.4M | -$39.7M |
| Amortizaciones | $1343 | $2632 | $1753 | $893 | $152364 | $164868 | $179677 | $194316 | $209611 | $214250 |
| Compensación en Acciones | $732151 | $986620 | $779701 | $715983 | $803261 | $1.5M | $3.9M | $6.6M | $11.8M | $10.8M |
| Cambio en Capital Circulante | $668163 | $115518 | $509846 | $2.2M | -$866968 | -$2.7M | $239555 | -$4.0M | -$1.7M | $1.1M |
| Flujo de Caja Operativo | -$5.9M | -$8.0M | -$11.3M | -$12.4M | -$16.9M | -$24.3M | -$28.4M | -$29.1M | -$28.2M | -$26.6M |
| Inversiones (CapEx) | 0 | -$2126 | 0 | 0 | -$1831 | -$40.0M | 0 | 0 | 0 | 0 |
| Adquisiciones | $255748 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$5.9M | -$8.0M | -$11.3M | -$12.4M | -$16.9M | -$64.3M | -$28.4M | -$29.1M | -$28.2M | -$26.6M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$11.9M | -$13.0M | -$1.3M | -$8.7M |
| Inversiones (CapEx) | $4 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$11.9M | -$13.0M | -$1.3M | -$8.7M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $2.9M | $4.3M | $3.8M | 0 |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | -25.2% | -20.7% | -24.3% | -12.6% | -31.4% | -45.9% | +3.3% | -20.3% | +4.4% |
| Crecimiento BPA (anual) | | +17.5% | +38.1% | +34.2% | -1354.5% | +49.6% | -2.0% | +3.1% | -7.2% | +43.4% |
| Cambio en Acciones (anual) | | +51.3% | +95.7% | +87.9% | +16.6% | +177.3% | +34.5% | +3.6% | +91.5% | -4.5% |
| Crecimiento FCF (anual) | | -35.1% | -41.9% | -9.9% | -36.1% | -279.5% | +55.9% | -2.5% | +3.0% | +5.8% |
| Tasa Impositiva Efectiva | -0.1% | -0.0% | -0.0% | -0.1% | -0.0% | -0.0% | -1.7% | -1.8% | -1.5% | -2.7% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-24.43 | $-21.81 | $-15.82 | $-9.25 | $-10.81 | $-14.79 | $-4.85 | $-4.80 | $-2.43 | $-2.40 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $241547 | $365500 | $715458 | $1.3M | $1.6M | $4.3M | $5.8M | $6.1M | $11.6M | $11.1M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -67.15% |
| Rentabilidad sobre capital invertido | -67.62% |
| Rentabilidad sobre activos | -32.53% |
| Margen bruto | 19.97% |
| Margen operativo | -863.92% |
| Margen neto | -651.27% |
Salud financiera
| Deuda / Patrimonio | 0.11 |
| Ratio corriente | 0.84 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -103.11 | -41.70 | -35.68 | -24.60 | -2.32 | -9.00 | -5.26 | -3.07 | -2.10 | -0.37 |
| P/VC | 3.40 | 1.31 | 1.07 | 1.04 | 1.21 | 1.67 | 1.72 | 1.14 | 2.07 | 0.20 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |